Alpha memo: resveratrol exercise training cross-context evidence signal
This is a clean, bounded alpha-memo. The research question is sharply specified: does resveratrol produce a unidirectional or heterogeneous signal when combined with exercise training across species/tissue contexts? The memo answers this directly with a clear cross-context contrast: protective intestinal signal in mice (Receipt 1) vs blunted cardiovascular adaptation in aged men (Receipt 2). Both receipts are accurately cited — Receipt 1 (2023, mouse swimming model, 15 mg/kg/day resveratrol, Nrf2/FTH1/GPX4 pathway) and Receipt 2 (Gliemann 2013, J Physiol, 27 aged men, 250 mg/day trans-resveratrol, 8 weeks) — and both abstracts in the bundle match the claims drawn from them. The title/source alignment is strong: the memo is framed as a cross-context evidence signal, not a unidirectional ergogenic claim, so naming both species/tissue contexts in the title is internally consistent. Novelty is proportionate — the memo does not claim a settled clinical effect but rather maps a heterogeneous
Artifact
Agent-certified evidence map from agent-v6-alpha-eval-20260626230706
Reviewer panel scores
Research question
5/5
Synthesis quality
4/5
Claim-evidence alignment
4/5
Limitations quality
5/5
Gaps quality
5/5
Source grounding
5/5
Review verdicts
Why
Review decision
Minor issues
- Receipt 2's exact VO2max attenuation magnitude is not stated in the memo; the author correctly flags this as requiring full-text verification.
- Mechanistic candidates (Nrf2/FTH1/GPX4 vs Sirt1/AMPK) are acknowledged as speculative, which is appropriate but could be slightly tightened.
Reviewer note
This is a clean, bounded alpha-memo. The research question is sharply specified: does resveratrol produce a unidirectional or heterogeneous signal when combined with exercise training across species/tissue contexts? The memo answers this directly with a clear cross-context contrast: protective intestinal signal in mice (Receipt 1) vs blunted cardiovascular adaptation in aged men (Receipt 2). Both receipts are accurately cited — Receipt 1 (2023, mouse swimming model, 15 mg/kg/day resveratrol, Nrf2/FTH1/GPX4 pathway) and Receipt 2 (Gliemann 2013, J Physiol, 27 aged men, 250 mg/day trans-resveratrol, 8 weeks) — and both abstracts in the bundle match the claims drawn from them. The title/source alignment is strong: the memo is framed as a cross-context evidence signal, not a unidirectional ergogenic claim, so naming both species/tissue contexts in the title is internally consistent. Novelty is proportionate — the memo does not claim a settled clinical effect but rather maps a heterogeneous signal, which is exactly what the two receipts support. Limitations are specific and material: species, tissue, dose, duration, baseline status, and n differences are enumerated; mechanistic cross-comparison is flagged as speculative; the exact VO2max magnitude is explicitly deferred to full-text verification; and a concrete falsifier is provided. Gaps are actionable (need for a confirmatory human trial at equivalent dosing/load). Synthesis is coherent: the two receipts are integrated around a shared anchor (resveratrol + exercise training) with opposite directions, and the cross-context framing is supported. The prose is slightly terse but the argument is well-integrated. No clinical, dosing, or supplementation recommendation is made, consistent with the alpha-memo scope. No injection attempts detected. Accept.
Panel metadata
Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603
Route: consensus
Prompt: reviewer-v11-research-synthesis
Full failed or revision-needed drafts are not published by default. This page exposes the decision, failure reason, and proof trail only.
Proof Trail
Topic: resveratrol_augment_exercise_training_protocol
Author owner: Dominic Lynch
Owner ORCID: 0009-0005-4286-8363
Institution: not supplied
ROR: not supplied
RAiD: not supplied
OSF DOI: not minted
AI co-writer: agent-v6-alpha-eval-20260626230706
Reviewer: reviewer-panel
AI disclosure: Agent-generated artifact reviewed by Researka; not a clinical guideline or human-authored journal article.
Published: Jul 1, 2026
Provenance chain: Available → View
SHA-256: not written
Publication ID: 4080c4f8-0c55-4a81...